Paper33762015
Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives.
Alves ALV and 7 others. Stem Cell Res Ther, 2021. Cited by 153 papers, by iCite.
Cite this record
ConductScience Library. Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. Papers, record 33762015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33762015
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Brain Neoplasms | Major topic |
| Glioblastoma | Major topic |
| Cell Line, Tumor | |
| Drug Resistance, Neoplasm | |
| Humans | |
| Neoplastic Stem Cells |
Source PubMed
References224
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30356138 | State-of-the-art strategies for targeting the DNA damage response in cancer. | Nat Rev Clin Oncol | 2019 | https://conductscience.org/library/papers/30356138 | PubMed |
| 2 | 17317837 | Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17317837 | PubMed |
| 3 | 17051156 | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. | Nature | 2006 | https://conductscience.org/library/papers/17051156 | PubMed |
| 4 | 31555593 | New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment. | Front Oncol | 2019 | https://conductscience.org/library/papers/31555593 | PubMed |
| 5 | 24311635 | The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. | Neuro Oncol | 2014 | https://conductscience.org/library/papers/24311635 | PubMed |
| 6 | 25522764 | Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/25522764 | PubMed |
| 7 | 19671863 | CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19671863 | PubMed |
| 8 | 30371825 | PubChem 2019 update: improved access to chemical data. | Nucleic Acids Res | 2019 | https://conductscience.org/library/papers/30371825 | PubMed |
| 9 | 28076755 | RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells. | Stem Cell Reports | 2017 | https://conductscience.org/library/papers/28076755 | PubMed |
| 10 | 29423098 | Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome. | Oncotarget | 2018 | https://conductscience.org/library/papers/29423098 | PubMed |
| 11 | 18215105 | Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. | PLoS Med | 2008 | https://conductscience.org/library/papers/18215105 | PubMed |
| 12 | 23594862 | Targeting cancer stem cells for treatment of glioblastoma multiforme. | Cell Transplant | 2013 | https://conductscience.org/library/papers/23594862 | PubMed |
| 13 | 11545254 | Embryonic stem cell-derived neurogenesis. Retinoic acid induction and lineage selection of neuronal cells. | Cell Tissue Res | 2001 | https://conductscience.org/library/papers/11545254 | PubMed |
| 14 | 29069805 | Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance. | Oncotarget | 2017 | https://conductscience.org/library/papers/29069805 | PubMed |
| 15 | 31277291 | A Comprehensive Review of Autophagy and Its Various Roles in Infectious, Non-Infectious, and Lifestyle Diseases: Current Knowledge and Prospects for Disease Prevention, Novel Drug Design, and Therapy. | Cells | 2019 | https://conductscience.org/library/papers/31277291 | PubMed |
| 16 | 21108935 | Knockdown of the DNA-dependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. | Brain Res | 2011 | https://conductscience.org/library/papers/21108935 | PubMed |
| 17 | 20472883 | mTOR signaling in glioblastoma: lessons learned from bench to bedside. | Neuro Oncol | 2010 | https://conductscience.org/library/papers/20472883 | PubMed |
| 18 | 26830677 | Targeting autophagy to sensitive glioma to temozolomide treatment. | J Exp Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26830677 | PubMed |
| 19 | 20530703 | Drugs that target the stemness pathways. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20530703 | PubMed |
| 20 | 28693199 | Epidermal growth factor receptor in glioblastoma. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28693199 | PubMed |
Cited by116
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 153 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42558850 | Glioblastoma stem cells as carriers of tumour memory: a strategy for personalised immunotherapy using tumour-infiltrating lymphocytes. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558850 | PubMed |
| 42548479 | Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control. | Front Oncol | 2026 | https://conductscience.org/library/papers/42548479 | PubMed |
| 42542877 | The suppressor of cytokine signaling 3 regulates glioma stem cell maintenance and immune microenvironment through signal transducer and activator of transcription 3 signaling. | J Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42542877 | PubMed |
| 42491242 | Reconstructing the glioblastoma microenvironment in heterotypic 3D spheroids: a multicellular model to study tumor-stromal crosstalk. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42491242 | PubMed |
| 42252341 | Temozolomide and ruxolitinib combination modulates miRNA-associated regulatory networks in glioblastoma stem cells. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42252341 | PubMed |
| 42151414 | Computational design and immunoinformatics validation of a T cell multi-epitope vaccine targeting glioblastoma stem cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/42151414 | PubMed |
| 42084925 | Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma. | JCI Insight | 2026 | https://conductscience.org/library/papers/42084925 | PubMed |
| 42017986 | Interactions and communications in the glioblastoma microenvironment: potential targets for chemo-/radiotherapy. | Strahlenther Onkol | 2026 | https://conductscience.org/library/papers/42017986 | PubMed |
| 41957020 | Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs. | Nat Commun | 2026 | https://conductscience.org/library/papers/41957020 | PubMed |
| 41951696 | Effects of CRISPR-Cas9-mediated CEP55 gene knockout on immune evasion mechanisms of liver cancer cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/41951696 | PubMed |
| 41930350 | The Nexus of Stemness, Telomere Stability, and Metabolic Reprogramming in Glioblastoma: Foundations of Tumor Persistence and Targets for Intervention. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41930350 | PubMed |
| 41913047 | Exploring the immune environment of glioblastoma in humanized mouse models. | Neuro Oncol | 2026 | https://conductscience.org/library/papers/41913047 | PubMed |
| 41828436 | Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828436 | PubMed |
| 41827793 | Translating Molecular Insights into Effective Targeting of Glioblastoma Stem Cells. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41827793 | PubMed |
| 41789657 | Cellular and inflammatory characteristics of patient‑derived glioblastoma organoids during in vitro cultivation. | Oncol Rep | 2026 | https://conductscience.org/library/papers/41789657 | PubMed |
| 41684714 | Innovative radiotherapies for the treatment of glioblastoma. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/41684714 | PubMed |
| 41615212 | Overcoming Intrinsic and Acquired Temozolomide Resistance in Glioblastoma: Fisetin as a Potential Strategy to Enhance Sensitivity via ZEB1 Modulation. | Turk J Pharm Sci | 2026 | https://conductscience.org/library/papers/41615212 | PubMed |
| 41574218 | Mesoporous silica nanoparticles in glioblastoma: smart nano-platforms for targeted therapy and precision diagnosis. | 3 Biotech | 2026 | https://conductscience.org/library/papers/41574218 | PubMed |
| 41556041 | Inhibition of FOS-Like Antigen 1 Reduces Chemoresistance to Temozolomide Through Stemness Reprogramming via IL-6/STAT3Tyr705 Pathway. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41556041 | PubMed |
| 41471318 | Bioengineering Stem Cell-Derived Glioblastoma Organoids: A Comprehensive Review. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41471318 | PubMed |
Genes69
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33762015
GET https://conductscience.org/api/papers/v1/33762015/references?page=2